Arranon
(nelarabine)ApprovedSmall molecule
NovartisNelarabine is a chemotherapy medication used to treat certain types of blood cancers, specifically leukemia and lymphoma that have not responded to other treatments or have returned after previous therapy. It works by destroying cancer cells.[2] Arranon is currently approved and in use across 10 indications[4].[1]
Arranon is one of 137 small molecule programs targeting Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. It is currently in Approved.
10
Indications
31
Total Trials
8
Active Trials
136
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
148 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Arranon
NovartisApproved
Oncaspar
SServier
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Cellcept
RochePhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Tepadina
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia7 trials
T-cell acute lymphoblastic leukemia5 trials
Leukemia3 trials
Lymphoma2 trials
12 more indications
Treatment1 trial
Relapse1 trial
Cutaneous T-cell lymphoma1 trial
Lymphoid Malignancies1 trial
Lymphoblastic Lymphoma1 trial
Chronic Lymphocytic Leukemia1 trial
T lymphoblastic leukemia/lymphoma1 trial
Regulatory
FDA Approval Timeline[5]
Oct 28, 2005
ARRANON
NDA NDA021877
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Arranon drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for nelarabine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]